Literature DB >> 21993556

p53 rescue through HDM2 antagonism suppresses melanoma growth and potentiates MEK inhibition.

Zhenyu Ji1, Ching Ni Njauw, Michael Taylor, Victor Neel, Keith T Flaherty, Hensin Tsao.   

Abstract

Oncogenesis reflects an orchestrated interaction between misguided growth signals. Although much effort has been launched to pharmacologically disable activated oncogenes, one sidelined approach is the restoration of tumor suppressive signals. As TP53 is often structurally preserved, but functionally crippled, by CDKN2A/ARF loss in melanoma, rescue of p53 function represents an attractive point of vulnerability in melanoma. In this study, we showed that both p53 protein and activity levels in melanoma cells were strongly induced by nutlin-3, a canonical HDM2 antagonist. Among a test panel of 51 cell lines, there was a marked reduction in melanoma viability that was directly linked to TP53 status. Moreover, we also found that the melanoma growth suppression mediated by mitogen-activated protein kinase/extracellular signal-regulated kinase inhibition was potentiated by HDM2 antagonism. These results provide fundamental insights into the intact p53 circuitry, which can be restored through small molecule inhibitors and potentially deployed for therapeutic gain.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21993556     DOI: 10.1038/jid.2011.313

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  37 in total

Review 1.  Melanoma: from mutations to medicine.

Authors:  Hensin Tsao; Lynda Chin; Levi A Garraway; David E Fisher
Journal:  Genes Dev       Date:  2012-06-01       Impact factor: 11.361

2.  AXL receptor signalling suppresses p53 in melanoma through stabilization of the MDMX-MDM2 complex.

Authors:  Anna de Polo; Zhongling Luo; Casimiro Gerarduzzi; Xiang Chen; John B Little; Zhi-Min Yuan
Journal:  J Mol Cell Biol       Date:  2017-04-01       Impact factor: 6.216

Review 3.  Oncogene-directed small molecule inhibitors for the treatment of cutaneous melanoma.

Authors:  Philip Eliades; Keith T Flaherty; Hensin Tsao
Journal:  Melanoma Manag       Date:  2015-05-18

Review 4.  Melanoma: new insights and new therapies.

Authors:  Vasiliki A Nikolaou; Alexander J Stratigos; Keith T Flaherty; Hensin Tsao
Journal:  J Invest Dermatol       Date:  2012-01-05       Impact factor: 8.551

5.  p53 Protein-mediated regulation of phosphoglycerate dehydrogenase (PHGDH) is crucial for the apoptotic response upon serine starvation.

Authors:  Yang Ou; Shang-Jui Wang; Le Jiang; Bin Zheng; Wei Gu
Journal:  J Biol Chem       Date:  2014-11-17       Impact factor: 5.157

6.  MDMX under stress: the MDMX-MDM2 complex as stress signals hub.

Authors:  Anna de Polo; Varunika Vivekanandan; John B Little; Zhi-Min Yuan
Journal:  Transl Cancer Res       Date:  2016-12       Impact factor: 1.241

Review 7.  Melanoma: clinical features and genomic insights.

Authors:  Elena B Hawryluk; Hensin Tsao
Journal:  Cold Spring Harb Perspect Med       Date:  2014-09-02       Impact factor: 6.915

8.  A mortalin/HSPA9-mediated switch in tumor-suppressive signaling of Raf/MEK/extracellular signal-regulated kinase.

Authors:  Pui-Kei Wu; Seung-Keun Hong; Sudhakar Veeranki; Mansi Karkhanis; Dmytro Starenki; Jose A Plaza; Jong-In Park
Journal:  Mol Cell Biol       Date:  2013-08-19       Impact factor: 4.272

Review 9.  Phytochemicals for the Management of Melanoma.

Authors:  Harish Chandra Pal; Katherine Marchiony Hunt; Ariana Diamond; Craig A Elmets; Farrukh Afaq
Journal:  Mini Rev Med Chem       Date:  2016       Impact factor: 3.862

10.  Growth inhibitory effects of large subunit ribosomal proteins in melanoma.

Authors:  Gregory R Kardos; Mu-Shui Dai; Gavin P Robertson
Journal:  Pigment Cell Melanoma Res       Date:  2014-06-16       Impact factor: 4.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.